Samuel Klempner, MD: The Role of the MATTERHORN Regimen in Resectable GC/GEJC

Dr. Samuel Klempner reviews key data from the MATTERHORN trial, which showed the benefit of perioperative durvalumab plus FLOT in the treatment of resectable gastric cancer/gastroesophageal function cancer. Dr. Klempner highlights EFS and OS gains with the MATTERHORN regimen, and briefly explores its role in clinical practice.